PitchSend

Nuvectis Pharma Investor Presentation Deck

Nuvectis Pharma - Key Highlights Our Approach to Precision Medicine NXP800 NXP900 Management Team with Strong Track Record Select and acquire novel, rationally-designed drug candidates → Focus on drug development for serious conditions of unmet need in oncology * Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma Phase 1b study ongoing in collaboration with ENGOT/GOG * Orphan Drug Designation for the treatment of cholangiocarcinoma U 7 Phase 1a commenced 3Q2023 First potential indications: YES1/SRC-driven solid tumors ❖ 3 approved drugs in 4 indications in the US and EU and multiple strategic deals Cash runway into 1H2025 3

View entire presentation